Review

The translational value of comparative oncology trials in client-owned dogs with spontaneous cancer: an overview of clinical trials initiated in dogs that resulted in phase I, II, or III clinical trials in human medicine

Authors

• • S. Janssen
• • J. Lievaart
• • L. Cicchelero
• • A. Krupa
• • N.C.H. do Valle
• • S. Vercammen
• • K. Verduijn
• • H. de Rooster

Abstract

Pet dogs with spontaneous cancer are a relevant translational model for human medicine. Several therapeutics evaluated in canine clinical trials progressed to clinical trials in humans. Promising results from comparative oncology trials in dogs provided good predictions of their safety and efficacy in human patients unlike many preclinical studies performed in murine models only. In this literature review, an overview is provided of clinical cancer studies initiated in pet dogs that have led to clinical trials in human patients and/or approval by the European or United States agencies responsible for drug approval. The results from these studies reveal the importance of clinical trials in dogs with spontaneous cancer that can pave the way for successful clinical trials in human cancer patients.

Keywords:

How to Cite: Janssen, S. , Lievaart, J. , Cicchelero, L. , Krupa, A. , do Valle, N. , Vercammen, S. , Verduijn, K. & de Rooster, H. (2025) “The translational value of comparative oncology trials in client-owned dogs with spontaneous cancer: an overview of clinical trials initiated in dogs that resulted in phase I, II, or III clinical trials in human medicine”, Vlaams Diergeneeskundig Tijdschrift. 94(4). doi: https://doi.org/10.21825/vdt.96230